TERPENOID THERAPEUTICS, INC.

Company Information

Company Name
TERPENOID THERAPEUTICS, INC.
Address
2501 Crosspark Road
Room B126-MTF
CORALVILLE, IA, 52241-3471
Phone
1 319-335-3899
URL
http://www.terpenoid.com
DUNS
602743903
Number of Employees
7
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$482,093.00
3
STTR Phase I
$455,864.00
3
STTR Phase II
$670,417.00
1
Chart code to be here

Award List

  1. Schweinfurthins: novel treatment for breast cancer

    Amount: $204,000.00

    DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Novel Glioblastoma Therapeutics

    Amount: $109,860.00

    DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schwein ...

    STTR Phase I 2007 Department of Health and Human Services
  3. Preclinical Development of Geranylgeranyl Disphosphate Synthase Inhibitors as Ant

    Amount: $123,123.00

    DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of moving our novel class of GGDPS specific inhibitors into clinical development for treat ...

    STTR Phase I 2007 Department of Health and Human Services
  4. Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.

    Amount: $114,959.00

    DESCRIPTION (provided by applicant): The goal of these studies is the development of a treatment for hormone refractory prostate cancer based on the inhibition of an enzyme geranygeranyl disphosphate ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Developing Schweinfurthin Analogs as Glioma Therapies

    Amount: $670,417.00

    DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that ...

    STTR Phase II 2009 Department of Health and Human Services
  6. Polaris Oncology Survivor Transition (POST) System

    Amount: $163,134.00

    DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated ...

    SBIR Phase I 2013 Department of Health and Human Services
  7. Targeting the chondrosarcoma extracellular matrix for drug delivery

    Amount: $222,881.00

    DESCRIPTION (provided by applicant): Chondrosarcoma is the second most common primary tumor of the bone having an incidence of 8 per million people in the US population over age 80. Research, particu ...

    STTR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government